Read by QxMD icon Read

Serotypes pneumococcal

Michael Pichichero, Ravinder Kaur, Daniel A Scott, William C Gruber, James Trammel, Anthony Almudevar, Kimberly J Center
BACKGROUND: With wide use of the seven-valent pneumococcal conjugate vaccine (PCV7) for protection against acute otitis media caused by Streptococcus pneumoniae serotypes included in the vaccine, efficacy testing for the 13-valent vaccine (PCV13) was not feasible. We aimed to assess the effectiveness of PCV13 in preventing acute otitis media caused by the six serotypes in PCV13 that were not in PCV7. METHODS: We did a longitudinal observational study in healthy children seen as outpatients in a private paediatric practice in Rochester, NY, USA...
August 2018: Lancet Child & Adolescent Health
M Nadeem Khan, Karin Pryharski, Michael E Pichichero
BACKGROUND: In the current transmission, we studied the immunogenicity and protective efficacy of serotypes 22F and 33F in the prevention of colonization and of invasive Streptococcus pneumoniae (Spn) pathogenesis during an influenza co-infection. Serotypes 22F and 33F are emerging Spn serotypes, which are not part of currently administered pneumococcal conjugate vaccine formulations (PCVs). Spn serotype 6A is an ingredient in the currently administered PCV13 vaccine and was therefore included in the study as a control...
August 11, 2018: Vaccine
Dimitrios Chanouzas, Michael Sagmeister, Sian Faustini, Peter Nightingale, Alex Richter, Charles J Ferro, Matthew David Morgan, Paul Moss, Lorraine Harper
Background: Infection is the leading cause of death in ANCA-associated vasculitis (AAV). Expansion of CD4+CD28null T-cells is associated with increased risk of infection and mortality, but is only present in cytomegalovirus-seropositive individuals. We hypothesised that subclinical cytomegalovirus reactivation drives CD4+CD28null T-cell expansion; that this is associated with impaired immune response to heterologous antigens, and that anti-viral therapy may ameliorate this. Methods: In a proof-of-concept open-label clinical trial, 38 cytomegalovirus-seropositive AAV patients were randomised to receive valaciclovir for 6-months or no intervention...
August 9, 2018: Journal of Infectious Diseases
Camilla Adler Sørensen, Eva Fuglsang, Charlotte Sværke Jørgensen, Rikke Pilmann Laursen, Anni Larnkjær, Christian Mølgaard, Christian Ritz, Kim F Michaelsen, Karen Angeliki Krogfelt, Hanne Frøkiær
OBJECTIVES: To examine the effect of a combination of probiotics on the antibody response to pneumococcal and pertussis vaccination in Danish healthy children, aged 8-14 months, at the time of starting day care. Moreover, the cytokine response to LPS of whole blood was assessed. METHODS: A total of 290 children were randomly allocated to receive a combination of Bifidobacterium animalis ssp. lactis and Lactobacillus rhamnosus GG daily for a six month intervention period, and blood samples were drawn at start and end of the study...
August 9, 2018: Clinical Microbiology and Infection
Danka Pavliakova, Peter C Giardina, Soraya Moghazeh, Shite Sebastian, Maya Koster, Viliam Pavliak, Andrew McKeen, Roger French, Kathrin U Jansen, Michael Pride
A Luminex-based direct immunoassay (dLIA) platform has been developed to replace the standardized pneumococcal enzyme-linked immunosorbent assay platform. The multiplex dLIA simultaneously measures the concentration of serum immunoglobulin G (IgG) antibodies specific for pneumococcal capsular polysaccharide (PnPS) serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. The assay uses poly-l-lysine (PLL)-conjugated PnPS, chemically coupled to spectrally distinct Luminex microspheres. Assay validation experiments were performed using residual human serum samples obtained from 13-valent pneumococcal conjugate vaccine (13vPnC) clinical studies...
August 8, 2018: MSphere
Charles Y Tan, Fred W Immermann, Shite Sebastian, Michael W Pride, Danka Pavliakova, Kelly A Belanger, Wendy Watson, Daniel A Scott, Mohinder Sidhu, Kathrin U Jansen, Peter C Giardina
This article describes the results of a study designed to bridge the World Health Organization (WHO) pneumococcal enzyme-linked immunosorbent assay (ELISA) platform to the validated Luminex-based 13-plex direct immunoassay (dLIA) platform developed by Pfizer, Inc. Both assay platforms quantify serotype-specific serum IgG antibodies (in micrograms per milliliter) against an international reference standard serum. The primary goal of this study was to determine if the dLIA is a suitable replacement for the ELISA to support clinical vaccine studies that include the evaluation of immune responses to serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F...
August 8, 2018: MSphere
Carlos Castañeda-Orjuela, Fernando De la Hoz-Restrepo
BACKGROUND: Children immunization with pneumococcal conjugate vaccine (PCV) had profound public health effects across the globe. Colombian adopted PCV10 universal vaccination, but PCV incremental impact need to be revalued. The objective of this analysis was to estimate the cost-effectiveness of switch to PCV13 versus continue PCV10 in Colombian children. METHODS: A complete economic analysis was carried-out assessing potential epidemiological and economic impact of switching from PCV10 to PCV13...
August 4, 2018: Vaccine
Soon Min Lee, Jang Hoon Lee, Eun Song Song, Sung Jin Kim, Joon Hyung Kim, Rupert W Jakes, Raghavendra Devadiga, Moon Sung Park
In 2010, Korea introduced 10-valent pneumococcal conjugate vaccine for children aged 6 weeks to 5 years against invasive disease caused by Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F and cross-reactive 19A. The aim of this 6-year real-world study of 646 healthy Korean children from 16 centers vaccinated in routine practice is to monitor vaccine safety, as per Ministry of Food and Drug Safety regulations. Around 50% had a past or existing medical condition, 19.3% an existing condition and 7...
August 7, 2018: Human Vaccines & Immunotherapeutics
Helene A S Ingels, Bjørn Kantsø, Hans-Christian Slotved
BACKGROUND: Some children are prone to recurrent invasive pneumococcal disease (rIPD) and of these, some respond insufficiently to standard pneumococcal vaccination. Little is known about how to handle these children and if they benefit from additional vaccination. Here, we present results from a nationwide study of pediatric rIPD including data on serotype-specific vaccination response to pneumococcal polysaccharide vaccination (PPV23) and pneumococcal conjugate vaccination (PCV7/13)...
August 6, 2018: BMC Infectious Diseases
David Cleary, Vanessa Devine, Denise Morris, Karen Osman, Rebecca Gladstone, Stephen Bentley, Saul Faust, Stuart Clarke
The implementation of pneumococcal conjugate vaccines (PCVs) has led to a decline in vaccine-type disease. However, there is evidence that the epidemiology of non-typeable Haemophilus influenzae (NTHi) carriage and disease can be altered as a consequence of PCV introduction. We explored the epidemiological shifts in NTHi carriage using whole genome sequencing over a 5-year period that included PCV13 replacement of PCV7 in the UK's National Immunization Programme in 2010. Between 2008/09 and 2012/13 (October to March), nasopharyngeal swabs were taken from children <5 years of age...
August 6, 2018: Microbial Genomics
Emmanouil I Koutouzis, George L Daikos, Panagiota Chatzichristou, Athanasios G Michos, Foteini I Koutouzi, George P Chrousos, Vassiliki P Syriopoulou
BACKGROUND: The present study assessed the prevalence and characteristics of S. pneumoniae serotype 19A isolates from children with pneumococcal disease (PD), before and since introduction of pneumococcal conjugate vaccines (PCVs) in Greece. METHODS: S. pneumoniae isolates collected at one large pediatric hospital between 1986 and 2015 were serotyped by the Quellung reaction and MICs determined by Etest. Alterations of pbp genes and the presence of mefA, mefE, ermB genes were detected by polymerase chain reaction...
August 23, 2018: Vaccine
Jong Hun Kim, Seung Hee Baik, Byung Chul Chun, Joon Young Song, In-Gyu Bae, Hyo Youl Kim, Dong-Min Kim, Young Hwa Choi, Won Suk Choi, Yu Mi Jo, Hyun Hee Kwon, Hye Won Jeong, Yeon-Sook Kim, Jeong Yeon Kim, Jacob Lee, Sae Yoon Kee, Jian Hur, Jin Won Chung, Ki-Eun Hwang, Min Ja Kim
OBJECTIVES: This study aimed to characterize mortality risk factors of adult invasive pneumococcal disease (IPD) stratified by age groups, after implementation of the national immunization program of 23-valent polysaccharide vaccine (PPSV23) for the elderly ≥65 years in the Republic of Korea (ROK). METHODS: Clinical data and pneumococcal isolates from adult patients with IPD (≥18 years) were prospectively collected from 20 hospitals through the nationwide surveillance program from March 2013 to October 2015...
July 25, 2018: International Journal of Infectious Diseases: IJID
Alfonso Carmona Martinez, Roman Prymula, Mariano Miranda Valdivieso, Maria Del Carmen Otero Reigada, Jose Manuel Merino Arribas, Jerzy Brzostek, Leszek Szenborn, Renata Ruzkova, Michael R Horn, Teresa Jackowska, Fernando Centeno-Malfaz, Magali Traskine, Kurt Dobbelaere, Dorota Borys
BACKGROUND: We assessed 2 investigational 11- and 12-valent vaccines, containing capsular polysaccharides of 10 serotypes as in the pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) and CRM197 -conjugated capsular polysaccharides of serotypes 19A (11-valent) or 19A and 6A (12-valent). METHODS: In this phase II, partially-blind, multicentre study (NCT01204658), healthy infants were randomised (1:1:1:1) to receive 11vPHiD-CV, 12vPHiD-CV, PHiD-CV, or 13-valent CRM197 -conjugate pneumococcal vaccine (PCV13), at 2, 3, and 4 (primary series), and 12-15 months of age (booster dose), co-administered with DTPa-HBV-IPV/Hib...
July 24, 2018: Vaccine
Naim Ouldali, Corinne Levy, Emmanuelle Varon, Stéphane Bonacorsi, Stéphane Béchet, Robert Cohen, François Angoulvant
BACKGROUND: Successive implementation of seven-valent then 13-valent pneumococcal conjugate vaccines (PCVs) led to a marked decrease in pneumococcal disease burden, including pneumococcal meningitis. We assessed the long-term effect of implementation of PCVs on incidence of pneumococcal meningitis in children in France over a 16-year period. METHODS: We did a quasi-experimental, population-based interrupted time-series analysis with a nationwide prospective survey over 16 years in France, recruiting children aged younger than 15 years from 227 paediatric wards from January, 2001, to December, 2016...
July 23, 2018: Lancet Infectious Diseases
Min Yong Jwa, Soyoung Jeong, Eun Byeol Ko, A Reum Kim, Hyun Young Kim, Sun Kyung Kim, Ho Seong Seo, Cheol-Heui Yun, Seung Hyun Han
Streptococcus pneumoniae is a major respiratory pathogen that causes millions of deaths worldwide. Although subunit vaccines formulated with the capsular polysaccharides or their protein conjugates are currently-available, low-cost vaccines with wide serotype coverage still remain to be developed, especially for developing countries. Recently, gamma- irradiation has been considered as an effective inactivation method to prepare S. pneumoniae vaccine candidate. In this study, we investigated the immunogenicity and protective immunity of gamma-irradiated S...
August 2018: Journal of Microbiology / the Microbiological Society of Korea
Kunling Shen, Matthew Wasserman, Dongdong Liu, Yong-Hong Yang, Junfeng Yang, Greg F Guzauskas, Bruce C M Wang, Betsy Hilton, Raymond Farkouh
BACKGROUND: The burden of pneumococcal disease in China is high, and a 13-valent pneumococcal conjugate vaccine (PCV13) recently received regulatory approval and is available to Chinese infants. PCV13 protects against the most prevalent serotypes causing invasive pneumococcal disease (IPD) in China, but will not provide full societal benefits until made broadly available through a national immunization program (NIP). OBJECTIVE: To estimate clinical and economic benefits of introducing PCV13 into a NIP in China using local cost estimates and accounting for variability in vaccine uptake and indirect (herd protection) effects...
2018: PloS One
Hyun Young Kim, Sun Kyung Kim, Ho Seong Seo, Soyoung Jeong, Ki Bum Ahn, Cheol-Heui Yun, Seung Hyun Han
Dendritic cells (DCs) play an important role in antigen presentation, which is an essential step for the induction of antigen-specific adaptive immunity. Inactivated bacterial whole cell vaccines have been widely used to prevent many bacterial infections because they elicit good immunogenicity due to the presence of various antigens and are relatively inexpensive and easy to manufacture. Recently, gamma-irradiated whole cells of nonencapsulated Streptococcus pneumoniae were developed as a broad-spectrum and serotype-independent multivalent vaccine...
July 20, 2018: Molecular Immunology
Sara Caporuscio, Roberto Ieraci, Guido Valesini, Raffaela Teloni, Sabrina Mariotti, Francesca Romana Spinelli, Claudia Ferlito, Simonetta Salemi, Andrea Picchianti Diamanti, Giorgia Meneguzzi, Milica Markovic, Mayla Sgrulletti, Christina von Hunolstein, Luisa Ralli, Antonietta Pinto, Gerardo Salerno, Marco Canzoni, Maria Laura Sorgi, Bruno Laganà, Roberta Di Rosa, Roberto Nisini, Raffaele D'Amelio
Immunogenicity of 13-valent pneumococcal polysaccharide (PnPS) conjugate vaccine (PCV13) was evaluated in 38 rheumatoid arthritis patients under immunosuppressive treatment and 20 healthy controls (HC). Antibodies to all PnPS and diphtheria-toxin analogue conjugate protein were measured pre- (T0), 1 (T1), 6 (T2), 12 (T3) months post-immunization. Patients and HC had similar response to individual PnPS. Mean antibody levels to all PnPS but one doubled at T1 compared with T0, with T3 persistence for only 8-7/13 PnPS...
July 21, 2018: Clinical Immunology: the Official Journal of the Clinical Immunology Society
Angela Gentile, Julia Bakir, Verónica Firpo, Enrique V Casanueva, Gabriela Ensinck, Santiago Lopez Papucci, María F Lución, Hector Abate, Aldo Cancellara, Fabiana Molina, Andrea Gajo Gane, Alfredo M Caruso, Alejandro Santillán Iturres, Sofía Fossati
INTRODUCTION: In 2012, PCV13 was introduced into the National Immunization Program in Argentina, 2+1 schedule for children <2 years. Coverage rates for 1st and 3rd doses were 69% and 41.0% in 2012, 98% and 86% in 2013; 99% and 89% in 2014, respectively. The aims of this study were to evaluate impact of PCV13 on Consolidated Pneumonia (CP) and Pneumococcal Pneumonia (PP) burden, and to describe epidemiological-clinical pattern of PP during the three-year period following vaccine introduction...
2018: PloS One
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"